China 
Africa 
Explore chapters and articles related to this topic
Screening and Pharmacological Management of Neuropathic Pain
Published in Suvardhan Kanchi, Rajasekhar Chokkareddy, Mashallah Rezakazemi, Smart Nanodevices for Point-of-Care Applications, 2022
Manu Sharma, Ranju Soni, Kakarla Raghava Reddy, Veera Sadhu, Raghavendra V. Kulkarni
Muscle relaxants are widely used to reduce the symptoms of muscle spasms, pain, and hyperreflexia. Drugs having spasmolytic and neuromuscular blocking activity are categorized under muscle relaxants. Neuromuscular blockers do not exhibit any central nervous system activity in contrast to spasmolytic. They work by blocking the transmission of the signal at the neuromuscular endplate. They are often used during surgical procedures and in intensive care and emergency medicine to cause temporary paralysis [41].
Understanding clinician strategies for discussing driving fitness with patients: An initiative to improve provider-patient discussions about safe driving
Published in Traffic Injury Prevention, 2021
Arianna Unger, Flaura K. Winston, Dominique G. Ruggieri, Joshua Remba
Of perhaps greatest concern are the effects of medications such as opioids and skeletal muscle relaxants on patients’ ability to drive safely. Opioids frequently produce side effects such as fatigue, lightheadedness, and miosis, which can affect attentiveness and the ability to effectively navigate traffic (Hetland and Carr 2014). Similarly, skeletal muscle relaxants can cause patients to experience drowsiness, ataxia, reduced coordination, and blurred vision which may also affect driving ability (Hetland and Carr 2014). Opioids and several classes of skeletal muscle relaxants, along with an array of other medications prescribed for neurological conditions, have repeatedly been shown to increase the risk of crash involvement (Bramness et al. 2007; Hetland and Carr 2014; Li and Chihuri 2019).